Vivani Medical, Inc. - רווח לפני ניכוי ריבית, מסים, בלאי ופחת VANI

Geopolitical instability and sanctions are complicating implant logistics, slowing the registration of Vivani Medical technologies. In response, Vivani Medical is scaling the NanoPRISM system for automated drug delivery in diabetology. The EBITDA_Co trend on the GURU.Markets platform daily chart shows that 0.00 determines the current status of the parameter, confirming the brand's status as a progressive innovator in the eyes of investors.

This indicator measures the amount of cash generated by the core business before interest, taxes, depreciation, and amortization, determining the asset's actual ability to create net cash flow. By analyzing changes in EBITDA, an investor assesses the effectiveness of implementing ESG standards and energy-saving technologies in the production of Vivani Medical (VANI) drug delivery systems, which directly impacts operating profitability and the final valuation of the stock.